Search Results 561-570 of 16033 for alopecia

  1. Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations

    The purpose of this study is to evaluate the challenges, behavioral patterns, and preferences of minority patient participation in clinical trials. Also, to ...

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

  3. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    All prior treatment- related toxicities must be NCI-CTCAE v4 ≤ Grade 1 (except alopecia (permitted at any grade) and peripheral neuropathy (permitted at ...

  4. A Study to Evaluate Food on Gastrointestinal Toxicity and The Effect of Selumetinib in Adolescents with Neurofibromatosis Type 1 - Mayo Clinic

    − Have any other unresolved chronic toxicity with CTCAE Grade ≥ 2, except hair changes (such as alopecia or high lightening). Participants who have ...

  5. Study of Awareness and Detection of Familial Hypercholesterolemia (CASCADE-FH) - Mayo Clinic

    About this study. The CASCADE Familial Hypercholesterolemia Registry will track therapy, clinical outcomes, and patient-reported outcomes over time aiming ...

  6. Head and neck cancers - Doctors and departments - Mayo Clinic

    ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

  7. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer - Mayo Clinic

    Toxicities from previous anti-cancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less ...

  8. Adult health Skin care - Mayo Clinic

    Find out about adult health, including physical and mental health, relationships, and workplace issues.

  9. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

    Persistent clinically significant ≥ Grade 2 toxicities from previous chemotherapy (excluding alopecia, nausea, fatigue, anemia, and liver function tests [as ...

  10. A Clinical Use Application for the Humanitarian Use Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Primary or Secondary Liver Neoplasia - Mayo Clinic

    This protocol allows multiple treatments with TheraSphere® that may be delivered on an outpatient basis. Patients may receive a single dose to a liver lobe or ...